企業プロフィール
Agios Pharmaceuticals, Inc. 株価・ニュース・カタリスト
- ティッカー:
- AGIO
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
33.63 USD (+0.21%)
終値
最終更新: 2026年8月17日
1.58B USD
時価総額
株価変動の要因
As of Aug 17, 2026, AGIO was little changed and closed at $33.63. No new same-company headline was identified in the current news window.
企業概要
Rare Disease Hematology Company
Agios is a commercial-stage biopharmaceutical company focused on rare diseases, with a foundation in hematology. Its current business is anchored by mitapivat, sold as PYRUKYND and AQVESME, while the company expands into additional rare hematology and metabolic disease programs.
Mitapivat Commercial Expansion
Mitapivat generated $44.7 million in worldwide net revenue in the second quarter of 2026. U.S. revenue was driven by the launch of AQVESME in thalassemia, while ex-U.S. revenue reflected European approval and early demand in Gulf Cooperation Council countries. Mitapivat is now approved for adults with thalassemia in the U.S., Saudi Arabia, United Arab Emirates, and the EU.
Sickle Cell Disease Opportunity
Agios is pursuing mitapivat in sickle cell disease through the FDA accelerated approval pathway. The FDA granted Priority Review for the supplemental NDA, with a PDUFA date of November 1, 2026, and the company has started the REIGNITE confirmatory Phase 3 trial.
Pipeline Diversification
The company is broadening beyond mitapivat. It licensed cevidoplenib, an oral SYK inhibitor for immune thrombocytopenia, and plans Phase 3 development after CMC work. AG-236, an siRNA targeting TMPRSS6, is advancing into Phase 2/3 development for polycythemia vera, while AG-181 is in Phase 1b testing for PKU.
今後のカタリスト
- FDA PDUFA date for mitapivat in sickle cell disease on November 1, 2026.
- Phase 2 portion initiation for AG-236 in polycythemia vera in the second half of 2026.
- AG-181 Phase 1b data in PKU expected in the second half of 2026.
- Cevidoplenib Phase 3 development in ITP expected to begin in the first half of 2028.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。